Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563299 · ClinicalTrials.gov registry record · Phase 4
Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
A Phase 4 study, sponsored by Retina Vitreous Associates of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04563299 is a Phase 4 study that was terminated before completion, run by Retina Vitreous Associates of Florida. The registered enrollment target is 10 participants.
The verdict
NCT04563299, a Phase 4 study, was terminated before completion, sponsored by Retina Vitreous Associates of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections. Patients will be randomized into two cohorts (Cohort 1 and Cohort 2) and then followed for 3 consecutive injection visits. Treatment will be rendered at each injection visit based on the individualized routine established anti-VEGF injection interval for each patient.
Interventions
- DRUG Prednisolone Acetate
- DRUG Dextenza 0.4Mg Ophthalmic Insert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04563299
The ClinicalTrials.gov registry entry for NCT04563299 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Retina Vitreous Associates of Florida, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisolone Acetate is the first listed.
NCT04563299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04563299 about?
NCT04563299 is a clinical study titled "Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections". This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections. Patients will be randomized into two cohorts (Cohort 1 and Cohort 2) and then followed for 3 consecutive injecti...
What is the current status of trial NCT04563299?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-12-09. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT04563299?
The interventions under investigation include: Prednisolone Acetate (DRUG), Dextenza 0.4Mg Ophthalmic Insert (DRUG).
Who is sponsoring clinical trial NCT04563299?
This trial is sponsored by Retina Vitreous Associates of Florida, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.